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claims data to evaluate the relationship between dose modifications and persis-
tence among patients that receive 5 or more administrations. Methods: Using 
data from the Cardinal Health Specialty Solutions Revenue Cycle Management 
medical claims database, 267 patients who received 5 or more eribulin adminis-
trations and completed therapy between May 2014 and April 2015 were included 
in the analyses. The Relative Dose Intensity (RDI) methodology compared the 
intensity of dose received per day of treatment against expected dose (recom-
mended dose) intensity. RDI values and total number of eribulin administrations 
were calculated for each patient based on the presence or absence of either dose 
reduction and/or dose delay. Data was analyzed using an independent samples 
t-test. Results: An analysis of patient distribution revealed the mean number of 
eribulin administrations was 13.4 with a mean RDI of 85%. Persistence was statisti-
cally higher in patients that had eribulin therapy managed through dose delay and 
dose reduction strategies. Patients with no modification (100% RDI) received an 
average of 8.1 eribulin administrations. Patients with dose modification (81% RDI) 
received an average of 14.5 eribulin administrations (p < 0.001). ConClusions: 
Management of eribulin therapy in patients with MBC via dose delay and/or reduc-
tion resulted in a statistically significant increase in persistence among responding 
patients.
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objeCtives: There is currently no standard of care for patients with advanced 
pancreatic cancer (APC), including locally advanced and metastatic disease, 
who progressed following first-line therapy. Available treatment options have 
been limited by a lack of therapeutic breakthroughs, and primarily utilize dif-
ferent combinations and dosing schedules of established chemotherapeutic 
agents. The current review assesses the relative efficacy of new therapeutic 
agents tested, alone or in combination, since 2003 in patients with APC who 
progressed following gemcitabine-based therapy. Methods: A systematic 
literature review was performed in PubMed/MEDLINE, EMBASE and ASCO 
meeting abstracts between January 2003 and June 2015. This review identi-
fied randomized controlled trials (RCTs) and single-arm trials evaluating new 
post-gemcitabine regimens in patients with APC. Results: A total of 34 trials, 
evaluating 1263 patients, were identified. New agents that have been tested 
include small molecules (24 trials), antibodies (3 trials), nanotherapeutics 
(4 trials), and immunotherapies (3 trials). The majority of studies were small, 
single-arm trials (n= 27). RCTs (n= 7, enrolling 835 patients) were further investi-
gated as they represent the standard for demonstrating therapeutic efficacy. At 
the time of analysis, the only Phase 3 RCT to evaluate a new therapeutic agent 
in post-gemcitabine APC was the NAPOLI-1 trial (nanoliposomal irinotecan 
(MM-398, nal-IRI) + 5-fluorouracil and leucovorin (5FU/LV) versus 5FU/LV), which 
was a large, global study that demonstrated a statistically significant improve-
ment in overall survival in patients with metastatic disease, including heavily-
pretreated patients. ConClusions: The present review highlights the limited 
number of RCTs evaluating new therapeutic agents in patients with APC who 
previously received gemcitabine. Most new agents fail to be evaluated beyond 
small, uncontrolled trials of APC. Despite much research in this difficult-to-treat 
patient population with high unmet medical need, only one Phase 3 RCT of a 
new agent (nal-IRI) + 5FU/LV demonstrated significant improvement in overall 
survival in patients with APC who had progressed following gemcitabine-based 
therapy.
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objeCtives: This study aimed to determine the demographic features, treat-
ment pattern, medication adherence, survival rates and associated healthcare 
costs in patients with newly diagnosed Ph+ CML from Korean National health 
Insurance (NHI) claims database Methods: We conducted a longitudinal analy-
sis of patients with newly diagnosed Ph+ CML (ICD-10: C92.1) and started treat-
ment with imatinib in 2005 enrolled in the Korean NHI program. Patients were 
excluded if they had ≥ 1 claim with a diagnosis of other cancer within one year 
before diagnosis of CML. All data were retrieved from the NHI Database provided 
by National Health Insurance Corporation in Korea Results: In the study, a 
total of 8,986 patients with a diagnosis of Ph+ CML between January 1, 2004 and 
December 31, 2013 were identified. Among them, our study population consisted 
268 patients (mean age: 46.4±14.7 years, male: 57.4%) with the diagnosis of CML 
in 2005. The majority of patients (75.9%) initiated imatinib therapy at a starting 
dose was 400mg/day. With over 7 years of follow-up data, based on the 180-day 
gap definition of discontinuation, 33 (11.7%) patient was discontinued and discon-
tinuation period was 395.4±137.2 days (range: 189-1,023). Overall, 44.3% (n= 125) 
of patients were defined as Good Medication Possession Ratio (MPR) (≥ 90%) 
and 19.2% (n= 54) were as Poor MPR (< 70%). During follow-up period, 69 patients 
(24.5%) were deceased and the time to death for them was 3.18 years (1,159.5 ± 
845.1 days) after initiation of imatinib. Patients with Good MPR had significantly 
higher survival compared to patients with Poor MPR (p< 0.001). ConClusions: 
In a retrospective assessment of a large cohort of patients with CP-CML treated 
with imatinib, we have shown that nonadherence to therapy is important factor 
for survival. Adherence to therapy must be included as an important evaluation 
parameter in all future studies of CML
Limited information was available linking disease severity to QoL. ConClusions: 
In studies of patients receiving treatment for recurrent or metastatic SCCHN, 
median OS did not differ systematically among populations receiving regimens 
containing cetuximab, docetaxel, methotrexate, or paclitaxel. Among platinum-
refractory patients, no treatment was identified as having demonstrated signifi-
cant improvements in QoL.
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objeCtives: The purpose of the current meta-analysis was to compare the effi-
cacy of lipegfilgrastim (LIP) to pegfilgrastim (PEG) and filgrastim (FIL). Methods: 
EMBASE was searched for head-to-head trials examining the efficacy of LIP, PEG, or 
FIL. Outcomes included incidence of febrile neutropenia (FN), incidence of severe 
neutropenia (SN), duration of SN (DSN), and time to recovery of absolute neutrophil 
count (ANC). Direct comparisons of SN/FN between LIP and PEG were made using 
random-effects models estimating relative risk (RR). No trials directly compared 
LIP and FIL; indirect comparisons were made with PEG or placebo/no treatment 
(PLA) as the common comparator. For DSN/ANC recovery, generic inverse variance 
methods were employed. Results: Sixty-five studies were identified and 24 were 
included after full-text review and quality assessment via PRISMA criteria. Over all 
treatment cycles, LIP was non-inferior to PEG for risk of FN (RR 0.34, 95% CI: 0.05, 
2.14). The indirect estimate of FN for LIP versus FIL was also non-significant (RR 
0.22, 95% CI: 0.03, 1.51). For SN during cycle 1, LIP had a RR of 0.80 (95% CI: 0.63, 1.03) 
versus PEG and 0.79 (95% CI: 0.61, 1.03) versus FIL. For subsequent cycles, the RR 
was 0.53 (95% CI: 0.35, 0.79) LIP versus PEG and 0.45 (95% CI: 0.27, 0.75) versus FIL. 
Time to ANC recovery was significant: -1.75 days (95% CI: -2.61, -0.90) for LIP versus 
PEG and -1.88 days (95% CI: -2.82, -0.95) for LIP versus FIL. No comparions were 
significant for DSN. ConClusions: LIP showed non-inferiority to PEG for risk of 
at least one FN episode and SN in cycle 1. LIP was more effective than both PEG and 
FIL for prevention of SN in cycles 2-4 and reduced ANC recovery time. However for 
DSN differences were not significant. These results suggest that LIP is a possibly 
more effective treatment.
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objeCtives: Effectiveness of daily G-CSF prophylaxis can be decreased when 
given in short courses. The objective was to determine the difference in odds of 
FN-related hospitalizations with once per cycle G-CSF (pegfilgrastim) prophylaxis 
compared to daily G-CSF (filgrastim/lenograstim) prophylaxis for patients receiving 
high/intermediate FN-risk chemotherapy for breast cancer or Non-Hodgkin lym-
phoma (NHL). Methods: This retrospective cohort study used claims data from 
the Health Research Institute research database with < 4 million insured individuals 
in Germany. Patients receiving first-line, high/intermediate FN-risk chemotherapy 
for breast cancer or NHL from January 1, 2009 to December 31, 2013 were included 
and those cycles with G-CSF administration initiated ≤ 5 days following chemo-
therapy were assessed. G-CSF types were identified by ATC codes and FN-related 
hospitalizations within each cycle were identified by ICD-10-GM codes with a 
primary/secondary diagnosis of neutropenia (D70.1*, D70.7). Odds ratios (OR) for 
FN-related hospitalization and 95% confidence intervals (CI) were estimated with 
generalized estimating equation models and adjusted for age, gender, tumour type, 
metastatic status, cycle number, chemotherapy FN-risk and history of anaemia and 
surgery. Results: In total, 2,278 patients representing 7,918 cycles (6316 pegfil-
grastim, 1602 daily G-CSF) were included in the analysis; 2,037 (89%) patients had 
breast cancer and 241 (11%) had NHL. More than half of patients receiving pegfil-
grastim prophylaxis initiated it in cycle 1, primary prophylaxis, (56%) whereas 37% 
of patients receiving daily G-CSF prophylaxis initiated it in cycle 1. Three-quarters 
of patients receiving daily G-CSF were prescribed 5 or less doses in at least one 
cycle. Cycles with prophylactic daily G-CSF were associated with an increased 
risk of FN-related hospitalisations (adjusted OR= 2.19, 95% CI: 1.41-3.39; p-value 
< .001) in comparison to cycles with prophylactic pegfilgrastim. ConClusions: 
This comparative effectiveness analysis showed a significantly higher likelihood 
of FN-related hospitalizations in cycles with daily G-CSF prophylaxis versus those 
with pegfilgrastim prophylaxis.
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objeCtives: Eribulin mesylate is a microtubule inhibitor FDA approved for 
patients with MBC after treatment with at least two prior chemotherapeutic regi-
mens. The recommended dose of eribulin is 1.4 mg/m2 administered on Days 1 
and 8 of a 21-day cycle with options for dose modification (dose reduction/dose 
delay) based on severity and duration of specific toxicities. Recent studies, limited 
to the clinical trial setting, have shown dose modifications lead to greater treat-
ment persistence and improved patient outcomes. This study utilized real-world 
